Neurobiological Technologies Net Income
| NTII Stock | USD 0.0001 0.00 0.00% |
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurobiological Technologies, as well as the relationship between them.
Neurobiological Technologies Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.1885 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 5.7 M | 6 M | |
| Net Income | 5.7 M | 6 M | |
| Net Income From Continuing Ops | 5.7 M | 6 M | |
| Net Income Per Share | 0.10 | 0.11 | |
| Net Income Per E B T | 0.91 | 0.79 |
Neurobiological | Net Income | Build AI portfolio with Neurobiological Stock |
The Net Income trend for Neurobiological Technologies offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Neurobiological Technologies is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Neurobiological Technologies' Net Income Growth Pattern
Below is the plot of the Net Income of Neurobiological Technologies over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Neurobiological Technologies financial statement analysis. It represents the amount of money remaining after all of Neurobiological Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Neurobiological Technologies' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurobiological Technologies' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.94 M | 10 Years Trend |
|
Net Income |
| Timeline |
Neurobiological Net Income Regression Statistics
| Arithmetic Mean | 4,849,595 | |
| Geometric Mean | 4,713,784 | |
| Coefficient Of Variation | 18.38 | |
| Mean Deviation | 383,717 | |
| Median | 4,943,000 | |
| Standard Deviation | 891,258 | |
| Sample Variance | 794.3B | |
| Range | 4.4M | |
| R-Value | 0.56 | |
| Mean Square Error | 582.8B | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | 98,617 | |
| Total Sum of Squares | 12.7T |
Neurobiological Net Income History
Other Fundumenentals of Neurobiological Technologies
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Neurobiological Technologies Net Income component correlations
Neurobiological Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurobiological Technologies is extremely important. It helps to project a fair market value of Neurobiological Stock properly, considering its historical fundamentals such as Net Income. Since Neurobiological Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurobiological Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurobiological Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Neurobiological introduce new products? Factors like these will boost the valuation of Neurobiological Technologies. Anticipated expansion of Neurobiological directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Neurobiological Technologies's market price often diverges from its book value, the accounting figure shown on Neurobiological's balance sheet. Smart investors calculate Neurobiological Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Neurobiological Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neurobiological Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurobiological Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurobiological Technologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurobiological Technologies' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurobiological Technologies.
| 12/02/2025 |
| 03/02/2026 |
If you would invest 0.00 in Neurobiological Technologies on December 2, 2025 and sell it all today you would earn a total of 0.00 from holding Neurobiological Technologies or generate 0.0% return on investment in Neurobiological Technologies over 90 days. Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in Octo... More
Neurobiological Technologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurobiological Technologies' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurobiological Technologies upside and downside potential and time the market with a certain degree of confidence.
Neurobiological Technologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobiological Technologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurobiological Technologies' standard deviation. In reality, there are many statistical measures that can use Neurobiological Technologies historical prices to predict the future Neurobiological Technologies' volatility.Neurobiological Technologies Backtested Returns
We have found three technical indicators for Neurobiological Technologies, which you can use to evaluate the volatility of the firm. The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Neurobiological Technologies are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Neurobiological Technologies has perfect predictability. Overlapping area represents the amount of predictability between Neurobiological Technologies time series from 2nd of December 2025 to 16th of January 2026 and 16th of January 2026 to 2nd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurobiological Technologies price movement. The serial correlation of 1.0 indicates that 100.0% of current Neurobiological Technologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neurobiological Operating Income
Operating Income |
|
Based on the recorded statements, Neurobiological Technologies reported net income of 4.94 M. This is 98.55% lower than that of the Biotechnology sector and 92.94% lower than that of the Health Care industry. The net income for all United States stocks is 99.13% higher than that of the company.
Neurobiological Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobiological Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobiological Technologies could also be used in its relative valuation, which is a method of valuing Neurobiological Technologies by comparing valuation metrics of similar companies.Neurobiological Technologies is currently under evaluation in net income category among its peers.
Neurobiological Fundamentals
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | 5.43 M | ||||
| Shares Outstanding | 27.02 M | ||||
| Number Of Shares Shorted | 37.6 K | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0001 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 25.32 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Total Debt | 1.04 M | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Short Ratio | 0.09 X | ||||
| Target Price | 6.0 | ||||
| Beta | -572.78 | ||||
| Market Capitalization | 2.7 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
| Net Asset | 2.58 M |
About Neurobiological Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobiological Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobiological Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobiological Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is there potential for Biotechnology market expansion? Will Neurobiological introduce new products? Factors like these will boost the valuation of Neurobiological Technologies. Anticipated expansion of Neurobiological directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Neurobiological Technologies's market price often diverges from its book value, the accounting figure shown on Neurobiological's balance sheet. Smart investors calculate Neurobiological Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Neurobiological Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neurobiological Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurobiological Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.